Denali Therapeutics (NASDAQ:DNLI) posted its earnings results on Tuesday. The company reported $0.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.90, MarketWatch Earnings reports. The firm had revenue of $125.68 million for the quarter, compared to analyst estimates of $9.73 million.
Shares of NASDAQ DNLI traded up $2.35 during mid-day trading on Wednesday, reaching $24.55. The company had a trading volume of 559,023 shares, compared to its average volume of 321,004. Denali Therapeutics has a one year low of $12.32 and a one year high of $23.28. The stock has a market capitalization of $1.97 billion, a P/E ratio of -4.17 and a beta of 2.08.
A number of equities research analysts have recently weighed in on DNLI shares. ValuEngine downgraded Denali Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 29th. Cantor Fitzgerald cut Denali Therapeutics from an “overweight” rating to a “neutral” rating and set a $25.00 price target on the stock. in a research report on Tuesday, January 29th. Finally, Zacks Investment Research upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a research report on Thursday, January 3rd.
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Read More: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.